Furthermore, we are currently designing a targeted delivery system for this stable IL-10 isoform by conjugating it to tumor-specific antibodies (e.g., anti-EGFR) to improve intratumoral accumulation and therapeutic efficacy in preclinical models of colorectal carcinoma. The gene discussed is IL10; the disease is colorectal carcinoma.